FindTrial
Sign In

OSKIRA-Asia-1

A Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose Ranging Study in Asia Evaluating Efficacy and Safety of Fostamatinib in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate Therapy

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221801
Enrollment
Unknown
Registered
2012-05-28
Start date
2012-05-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

investigational material(s) Generic name etc : Fostamatinib INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investi

Sponsors

AstraZeneca
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Active rheumatoid arthritis (RA) diagnosed after the age of 16 - 6 or more swollen joints and 6 or more tender/painful joints from certain joints in the hands, wrists, arms and knees - At least one of: -positive result for rheumatoid factor test, either in the past or currently (blood test) -x-ray showing bone erosion within the last 12 months -presence of certain antibodies in the blood (blood test) - Currently taking methotrexate for at least 6 months (and on a stable dose for at least 6 weeks)

Exclusion criteria

Exclusion criteria: - Females who are pregnant or breast feeding - Certain inflammatory conditions (other than rheumatoid arthritis), connective tissue diseases or chronic pain disorders. - Previously taken, but not responded to, certain biological treatments for rheumatoid arthritis - High blood pressure that is not controlled by medication - Low levels of neutrophils in the blood (blood test).

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026